SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degeneration

Eye 2026 Open access

Read full text
Authors: Clare Bailey, C. Lange, Varun Chaudhary, Paolo Lanzetta, Hassiba Oubraham, Martin C Kirchner, Tobias Machewitz, Helmut Allmeier, Xin Zhang, Zoran Hasanbasic, Marion Rohit Munk, on behalf of the SPECTRUM study investigators
DOI: 10.1038/s41433-026-04260-3
Cited by: 2
References: 2

Abstract

The CANDELA and PULSAR trials demonstrated the efficacy and safety of intravitreal aflibercept 8 mg in the treatment of neovascular age-related macular degeneration (nAMD) [ 1 , 2 ]. SPECTRUM is the first global real-world study of aflibercept 8 mg in nAMD, and its unique study design enables rolling global and country cohort analyses. Here, we describe early clinical experience in the first ~100 patients with treatment-naïve (TN) or previously treated (PT) nAMD to have a visit and visual acuity (VA) assessment at Week 8 (W8) in SPECTRUM.

Fields of Study & Subjects

Retinal Diseases and Treatments Retinal Imaging and Analysis Ophthalmology and Visual Impairment Studies

Publication details

Journal / source
Eye
Publisher
Springer Science and Business Media LLC
Volume
40
Issue
5
Pages
735–738
Publication date
30 January 2026
Language
EN